宫颈非典型腺细胞女性中人乳头瘤病毒非16/18型别对宫颈上皮内瘤变3级或更差病变的风险评估
这项基于人群的队列研究对2014年2月17日至2018年12月31日瑞典341例宫颈细胞学为非典型腺细胞且HPV为非16/18型别的女性进行HPV基因分型,随访至2019年12月31日。随访期间134例(39.3%)发生CIN 3-AIS,仅5例(1.5%)为浸润性宫颈癌;HPV33阳性者中82.9%(95%CI 58.0-97.3%)发生CIN 3或更差病变,HPV31阳性者CIN 3或更差病变的HR最高(原发细胞学筛查HR 2.71,95%CI 1.47-5.00;原发HPV筛查HR 3.41,95%CI 1.95-5.96)。作者认为扩展HPV基因分型可能有助于非典型腺细胞的管理。
要点
- 341例AGC且非16/18 HPV阳性女性中,134例(39.3%)为CIN 3-AIS,5例(1.5%)为浸润性宫颈癌。
- HPV33阳性者中82.9%(95%CI 58.0-97.3%)随访期间发生CIN 3或更差病变。
- HPV31阳性者CIN 3或更差病变HR最高:原发细胞学筛查HR 2.71(95%CI 1.47-5.00),原发HPV筛查HR 3.41(95%CI 1.95-5.96)。
核心结论
- 在AGC女性的非16/18 HPV型别中,HPV31和HPV33与CIN 3或更差病变的风险最高,而多数浸润性癌女性为HPV45阳性。
- 作者认为扩展HPV基因分型可能有助于AGC的管理。
研究设计与样本
- 基于人群的队列研究,纳入2014年2月17日至2018年12月31日瑞典341例宫颈细胞学为AGC且HPV为非16/18型别的女性。
- 对Pap试验进行HPV基因分型,并通过综合登记 linkage 随访组织病理学结局至2019年12月31日。
- 采用1减Kaplan-Meier函数计算特定HPV型别的CIN 3或更差病变累积发生率比例,采用多因素Cox回归生成风险比(HR)。
主要发现
- 341例女性中134例(39.3%)为CIN 3-AIS,仅5例(1.5%)为浸润性宫颈癌。
- 80.0%的浸润性宫颈癌病例之前有HPV45。
- HPV33阳性女性中82.9%(95%CI 58.0-97.3%)在随访期间发生CIN 3或更差病变。
- HPV31阳性者CIN 3或更差病变的HR最高:原发细胞学筛查HR 2.71(95%CI 1.47-5.00),原发HPV筛查HR 3.41(95%CI 1.95-5.96)。
关键数值与推荐
- HPV33阳性者CIN 3或更差病变累积发生率比例为82.9%(95%CI 58.0-97.3%)。
- HPV31阳性者CIN 3或更差病变HR:原发细胞学筛查2.71(95%CI 1.47-5.00),原发HPV筛查3.41(95%CI 1.95-5.96)。
- 浸润性宫颈癌中80.0%之前有HPV45。
临床怎么用
- 作者认为扩展HPV基因分型可能有助于AGC的管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the risk for cervical intraepithelial neoplasia grade 3 (CIN 3) or worse (including adenocarcinoma in situ [AIS] and invasive cervical cancer) associated with non-16/18 human papillomavirus (HPV) types (other HPV) among women with atypical glandular cells (AGC) in cervical cytology. METHODS: This population-based cohort study evaluates the risk of CIN 3 or worse associated with other HPV types. Human papillomavirus genotyping was performed on Pap tests collected in Sweden from 341 women with AGC that were positive for other HPV types from February 17, 2014, to December 31, 2018. The women were followed for histopathologic outcomes using comprehensive registry linkages until December 31, 2019. Cumulative incidence proportions of CIN 3 or worse by specific HPV type were calculated using 1-minus Kaplan-Meier function. Hazard ratios (HRs) for CIN 3 or worse were generated using multivariate Cox regression. RESULTS: Of 341 women, 134 (39.3%) had CIN 3-AIS, but there were only five (1.5%) women in the cohort with invasive cervical cancer. Human papillomavirus 45 preceded 80.0% of invasive cervical cancer cases. Among women positive for HPV33, 82.9% (95% CI 58.0-97.3%) had CIN 3 or worse during follow-up. Positivity for HPV31 conferred the highest HR for CIN 3 or worse relative to other types, both in primary cytology and primary HPV screening (HR 2.71, 95% CI 1.47-5.00 and HR 3.41, 95% CI 1.95-5.96, respectively). CONCLUSION: Among non-16/18 HPV types in AGC, HPV31 and 33 had the highest risk for CIN 3 or worse, whereas most of the women with invasive cancer were positive for HPV45. Extended HPV genotyping may be helpful for the management of AGC.
引用
- Yilmaz E, Lagheden C, Ghaderi M, et al. Assessment of Human Papillomavirus Non-16/18, Type-Specific Risk for Cervical Intraepithelial Neoplasia Grade 3 or Worse Among Women With Cervical Atypical Glandular Cells. Obstet Gynecol. 2023. PMID: 37535949. doi:10.1097/AOG.0000000000005286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。